한글목차

약물난치성 뇌전증 세계 시장 규모는 2024년 18억 5,000만 달러, 2030년에는 24억 4,000만 달러에 달할 것으로 예상되며, 예측 기간 동안 연평균 성장률(CAGR)은 4.72%를 보일 것으로 예측됩니다.

이 시장은 기존 항경련제(AED)로 충분한 효과를 얻지 못하는 환자들의 미충족 수요에 초점을 맞춘 강력한 연구개발 활동을 통해 지속적으로 진화하고 있습니다.

간질은 발작의 재발이 특징인 신경질환으로 전 세계적으로 많은 환자가 앓고 있습니다. 난치성 간질이라고도 불리는 약물난치성 뇌전증은 두 가지 이상의 적절한 AED 치료에도 불구하고 발작이 지속되는 경우를 말합니다. 난치성 간질은 미충족 의료 수요가 높은 질환으로 전 세계 시장에서 기술 혁신과 투자가 활발히 진행되고 있습니다.

주요 시장 성장 촉진요인

간질 유병률 증가

주요 시장 이슈

복잡하고 고르지 않은 질병 프로파일

주요 시장 동향

신경 영상 기술의 발전

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 세계의 약물난치성 뇌전증 시장 전망

• 시장 규모와 예측
  • 금액별
• 시장 점유율과 예측
  • 치료 유형별(신경 조절 요법, 항간질약, 벤조디아제핀, 간질 절제 수술, 특정 대사 치료, 특정 유전자 치료, 면역치료)
  • 최종사용자별(병원 및 진료소, 외래 진료 센터, 기타)
  • 지역별
  • 기업별(2024년)
• 시장 맵
  • 치료 유형별
  • 최종사용자별
  • 지역별

제5장 아시아태평양의 약물난치성 뇌전증 시장 전망

• 시장 규모와 예측
  • 금액별
• 시장 점유율과 예측
  • 치료 유형별
  • 최종사용자별
  • 국가별
• 아시아태평양 : 국가별 분석
  • 중국
  • 인도
  • 호주
  • 일본
  • 한국

제6장 유럽의 약물난치성 뇌전증 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 유럽 : 국가별 분석
  • 프랑스
  • 독일
  • 스페인
  • 이탈리아
  • 영국

제7장 북미의 약물난치성 뇌전증 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 북미 : 국가별 분석
  • 미국
  • 멕시코
  • 캐나다

제8장 남미의 약물난치성 뇌전증 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 남미 : 국가별 분석
  • 브라질
  • 아르헨티나
  • 콜롬비아

제9장 중동 및 아프리카의 약물난치성 뇌전증 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 중동 및 아프리카 : 국가별 분석
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트(UAE)

제10장 시장 역학

• 성장 촉진요인
• 과제

제11장 시장 동향과 발전

• 최근 동향
• 제품 출시
• 인수합병(M&A)

제12장 세계의 약물난치성 뇌전증 시장 : SWOT 분석

제13장 Porter의 Five Forces 분석

• 업계내 경쟁
• 신규 참여 가능성
• 공급업체의 힘
• 고객의 힘
• 대체품의 위협

제14장 경쟁 구도

• UCB S.A.
• Jazz Pharmaceuticals
• LivaNova PLC
• NeuroPace, Inc
• Avenue Therapeutics
• Xenon Pharmaceuticals Inc.
• Marinus Pharmaceuticals
• PTC Therapeutics
• Aquestive Therapeutics
• Neuroelectrics

제15장 전략적 제안

제16장 리서치사에 대해 & 면책사항

영문목차

Global Drug-Resistant epilepsy market was valued at USD 1.85 billion in 2024 and is projected to reach USD 2.44 billion by 2030, registering a compound annual growth rate (CAGR) of 4.72% during the forecast period. This market continues to evolve, driven by robust research and development activities focused on addressing the unmet needs of patients who exhibit inadequate response to conventional anti-epileptic drugs (AEDs).

Epilepsy, a neurological condition characterized by recurrent seizures, affects a significant global population. Drug-resistant epilepsy-also known as refractory epilepsy-refers to cases in which patients continue to experience seizures despite treatment with two or more appropriate AEDs. This segment represents a substantial unmet clinical need, propelling innovation and investment across the global market landscape.

Key Market Drivers

Increasing Prevalence of Epilepsy

The rising global incidence of epilepsy is a primary factor fueling market growth. According to the World Health Organization (WHO), approximately 50 million individuals worldwide are affected by epilepsy. Of this population, an estimated 30% do not respond adequately to standard anti-seizure therapies, resulting in drug-resistant forms of the disorder.

As global demographics shift toward an aging population, the overall prevalence of epilepsy is expected to rise, contributing to an increased burden of drug-resistant cases. This trend underscores the urgent need for advanced therapeutic solutions tailored to this difficult-to-treat patient group.

Additionally, while up to 70% of epilepsy patients could potentially achieve seizure control with appropriate treatment, approximately 75% of individuals in low-income regions lack access to essential medications. This treatment gap highlights the critical importance of early diagnosis, improved access to care, and continued innovation in therapeutic options designed specifically for drug-resistant epilepsy.

Key Market Challenges

Complex and Heterogeneous Disease Profile

One of the most significant challenges in treating drug-resistant epilepsy is the condition's complex and heterogeneous nature. The disorder comprises a wide range of seizure types, each with distinct etiologies, clinical presentations, and treatment responses. This variability complicates efforts to develop universally effective therapies.

The evolving nature of drug-resistant epilepsy further contributes to its clinical complexity. Seizure patterns and drug efficacy may change over time, requiring continuous reassessment and adaptation of treatment strategies. As a result, the development of standardized interventions remains a major hurdle, necessitating a more personalized approach to care.

Key Market Trends

Advancements in Neuroimaging Technologies

Innovations in neuroimaging are significantly enhancing diagnostic and therapeutic capabilities in the drug-resistant epilepsy market. These advanced imaging techniques are transforming clinical approaches by providing deeper insights into brain structure and function.

Modern Magnetic Resonance Imaging (MRI) technologies-including functional MRI (fMRI), diffusion tensor imaging (DTI), and magnetic resonance spectroscopy (MRS)-offer high-resolution views of brain activity, connectivity, and subtle structural abnormalities. These tools are instrumental in identifying epileptic foci and guiding surgical or targeted treatment options.

Positron Emission Tomography (PET) also plays a crucial role by detecting metabolic irregularities in brain regions associated with seizure activity. Enhanced by advanced radiotracers and image processing methods, PET imaging facilitates more accurate diagnosis and localization of epileptic zones.

In addition, Single-Photon Emission Computed Tomography (SPECT) is widely used to assess cerebral blood flow during seizures, helping clinicians pinpoint seizure origins and inform personalized treatment planning. Collectively, these advancements are fostering a more precise and effective management paradigm for drug-resistant epilepsy.

Key Market Players

• UCB S.A.
• Jazz Pharmaceuticals
• LivaNova PLC
• NeuroPace, Inc
• Avenue Therapeutics
• Xenon Pharmaceuticals Inc.
• Marinus Pharmaceuticals
• PTC Therapeutics
• Aquestive Therapeutics
• Neuroelectrics

Report Scope:

In this report, the Global Drug-Resistant Epilepsy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Drug-Resistant Epilepsy Market, By Treatment Type:

• Neuromodulation Therapy
• Antiseizure Medications
• Benzodiazepines
• Resective Epilepsy Surgery
• Specific Metabolic Treatment
• Specific Genetic Treatment
• Immunotherapy

Drug-Resistant Epilepsy Market, By End User:

• Hospitals & Clinics
• Ambulatory Care Centers
• Others

Drug-Resistant Epilepsy Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Drug-Resistant Epilepsy Market.

Available Customizations:

Global Drug-Resistant Epilepsy Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Drug-Resistant Epilepsy Market Outlook

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
• 4.2. Market Share & Forecast
  • 4.2.1. By Treatment Type (Neuromodulation Therapy, Antiseizure Medications, Benzodiazepines, Resective Epilepsy Surgery, Specific Metabolic Treatment, Specific Genetic Treatment, Immunotherapy)
  • 4.2.2. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
  • 4.2.3. By Region
  • 4.2.4. By Company (2024)
• 4.3. Market Map
  • 4.3.1. By Treatment Type
  • 4.3.2. By End User
  • 4.3.3. By Region

5. Asia Pacific Drug-Resistant Epilepsy Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Treatment Type
  • 5.2.2. By End User
  • 5.2.3. By Country
• 5.3. Asia Pacific: Country Analysis
  • 5.3.1. China Drug-Resistant Epilepsy Market Outlook
    • 5.3.1.1. Market Size & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share & Forecast
      • 5.3.1.2.1. By Treatment Type
      • 5.3.1.2.2. By End User
  • 5.3.2. India Drug-Resistant Epilepsy Market Outlook
    • 5.3.2.1. Market Size & Forecast
      • 5.3.2.1.1. By Value
    • 5.3.2.2. Market Share & Forecast
      • 5.3.2.2.1. By Treatment Type
      • 5.3.2.2.2. By End User
  • 5.3.3. Australia Drug-Resistant Epilepsy Market Outlook
    • 5.3.3.1. Market Size & Forecast
      • 5.3.3.1.1. By Value
    • 5.3.3.2. Market Share & Forecast
      • 5.3.3.2.1. By Treatment Type
      • 5.3.3.2.2. By End User
  • 5.3.4. Japan Drug-Resistant Epilepsy Market Outlook
    • 5.3.4.1. Market Size & Forecast
      • 5.3.4.1.1. By Value
    • 5.3.4.2. Market Share & Forecast
      • 5.3.4.2.1. By Treatment Type
      • 5.3.4.2.2. By End User
  • 5.3.5. South Korea Drug-Resistant Epilepsy Market Outlook
    • 5.3.5.1. Market Size & Forecast
      • 5.3.5.1.1. By Value
    • 5.3.5.2. Market Share & Forecast
      • 5.3.5.2.1. By Treatment Type
      • 5.3.5.2.2. By End User

6. Europe Drug-Resistant Epilepsy Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Treatment Type
  • 6.2.2. By End User
  • 6.2.3. By Country
• 6.3. Europe: Country Analysis
  • 6.3.1. France Drug-Resistant Epilepsy Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Treatment Type
      • 6.3.1.2.2. By End User
  • 6.3.2. Germany Drug-Resistant Epilepsy Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Treatment Type
      • 6.3.2.2.2. By End User
  • 6.3.3. Spain Drug-Resistant Epilepsy Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Treatment Type
      • 6.3.3.2.2. By End User
  • 6.3.4. Italy Drug-Resistant Epilepsy Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Treatment Type
      • 6.3.4.2.2. By End User
  • 6.3.5. United Kingdom Drug-Resistant Epilepsy Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Treatment Type
      • 6.3.5.2.2. By End User

7. North America Drug-Resistant Epilepsy Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Treatment Type
  • 7.2.2. By End User
  • 7.2.3. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Drug-Resistant Epilepsy Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Treatment Type
      • 7.3.1.2.2. By End User
  • 7.3.2. Mexico Drug-Resistant Epilepsy Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Treatment Type
      • 7.3.2.2.2. By End User
  • 7.3.3. Canada Drug-Resistant Epilepsy Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Treatment Type
      • 7.3.3.2.2. By End User

8. South America Drug-Resistant Epilepsy Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Treatment Type
  • 8.2.2. By End User
  • 8.2.3. By Country
• 8.3. South America: Country Analysis
  • 8.3.1. Brazil Drug-Resistant Epilepsy Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Treatment Type
      • 8.3.1.2.2. By End User
  • 8.3.2. Argentina Drug-Resistant Epilepsy Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Treatment Type
      • 8.3.2.2.2. By End User
  • 8.3.3. Colombia Drug-Resistant Epilepsy Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Treatment Type
      • 8.3.3.2.2. By End User

9. Middle East and Africa Drug-Resistant Epilepsy Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Treatment Type
  • 9.2.2. By End User
  • 9.2.3. By Country
• 9.3. MEA: Country Analysis
  • 9.3.1. South Africa Drug-Resistant Epilepsy Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Treatment Type
      • 9.3.1.2.2. By End User
  • 9.3.2. Saudi Arabia Drug-Resistant Epilepsy Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Treatment Type
      • 9.3.2.2.2. By End User
  • 9.3.3. UAE Drug-Resistant Epilepsy Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Treatment Type
      • 9.3.3.2.2. By End User

10. Market Dynamics

• 10.1. Drivers
• 10.2. Challenges

11. Market Trends & Developments

• 11.1. Recent Developments
• 11.2. Product Launches
• 11.3. Mergers & Acquisitions

12. Global Drug-Resistant Epilepsy Market: SWOT Analysis

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Product

14. Competitive Landscape

• 14.1. UCB S.A.
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Current Capacity Analysis
  • 14.1.5. Financials (In case of listed)
  • 14.1.6. Recent Developments
  • 14.1.7. SWOT Analysis
• 14.2. Jazz Pharmaceuticals
• 14.3. LivaNova PLC
• 14.4. NeuroPace, Inc
• 14.5. Avenue Therapeutics
• 14.6. Xenon Pharmaceuticals Inc.
• 14.7. Marinus Pharmaceuticals
• 14.8. PTC Therapeutics
• 14.9. Aquestive Therapeutics
• 14.10. Neuroelectrics

15. Strategic Recommendations

16. About Us & Disclaimer